Company Seeks Marketing Approval for Possible Duchenne Muscular Dystrophy Drug in EU
Capri23auto / Pixabay

Company Seeks Marketing Approval for Possible Duchenne Muscular Dystrophy Drug in EU

According to a story from BioPortfolio, the specialty pharmaceutical company Santhera Pharmaceuticals recently announced that it has submitted its marketing application to the European Medicines Agency (EMA) for its drug…

Continue Reading Company Seeks Marketing Approval for Possible Duchenne Muscular Dystrophy Drug in EU

Program Established by the NIH to Help Rare Disease Advocacy Groups Start Patient Registries

The Beginnings Anne Pariser worked for 16 years at the FDA. For part of that time, she was a team leader for the Center for Drug Evaluation and Research where…

Continue Reading Program Established by the NIH to Help Rare Disease Advocacy Groups Start Patient Registries

New Collaboration is Dedicated to Developing a Gene Therapy for Congenital Muscular Dystrophy

According to a story from globenewswire.com, the specialty pharmaceutical company Santhera Pharmaceuticals will be entering a collaborative partnership with the University of Basel's Biozentrum. The goal of this partnership will…

Continue Reading New Collaboration is Dedicated to Developing a Gene Therapy for Congenital Muscular Dystrophy

After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear

According to a story from BioSpace, a Phase 1/2 clinical trial testing SGT-001, an investigational treatment for Duchenne muscular dystrophy, has been plagued by problems with side effects and adverse…

Continue Reading After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear

After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear

According to a story from BioSpace, a Phase 1/2 clinical trial testing SGT-001, an investigational treatment for Duchenne muscular dystrophy, has been plagued by problems with side effects and adverse…

Continue Reading After Issues With Adverse Events, the Future of This Experimental Duchenne Muscular Dystrophy Drug Remains Unclear

New Bill Could Allow Easier Access to Complex Rehabilitation Technology for Rare Disease Patients

H.R. 2408 H.R. 2408 is a new piece of federal legislation otherwise known as the "Ensuring Access to Quality Complex Rehabilitation Technology Act." Essentially, this act creates a new category…

Continue Reading New Bill Could Allow Easier Access to Complex Rehabilitation Technology for Rare Disease Patients
Duchenne Muscular Dystrophy Patient That Admired Stephen Hawking Passed Away During Exams…With Close to Perfect Scores
HarinathR / Pixabay

Duchenne Muscular Dystrophy Patient That Admired Stephen Hawking Passed Away During Exams…With Close to Perfect Scores

According to a story from m.dailyhunt.in, Vinayak Sreedhar, an Indian student with Duchenne muscular dystrophy, passed away in the midst of taking his exams. Vinayak was a driven and highly…

Continue Reading Duchenne Muscular Dystrophy Patient That Admired Stephen Hawking Passed Away During Exams…With Close to Perfect Scores

Researchers Believe Lithium May be Key to Developing a Drug for Limb Girdle Muscular Dystrophy

The News Hub at Washington State University recently carried an article describing initial success by researchers towards developing a drug for a rare form of muscular dystrophy. Several thousand people…

Continue Reading Researchers Believe Lithium May be Key to Developing a Drug for Limb Girdle Muscular Dystrophy

Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug

According to a press release from Massachusetts-based biotech company Fulcrum Therapeutics, the company has successfully secured global commercialization rights of GlaxoSmithKline-developed experimental facioscapulohumeral muscular dystrophy (FSHD) drug losmapimod. Losmapimod, an…

Continue Reading Fulcrum Therapeutics Acquires Experimental Facioscapulohumeral Muscular Dystrophy Drug
Muscular Dystrophy Association to Host First Annual Combined Conference
Hundreds of people living with narcolepsy gathered at the NN's 2015 Conference to make friends and learn something new. Source: Narcolepsy Network

Muscular Dystrophy Association to Host First Annual Combined Conference

A recent publication from Charcot-Marie-Tooth News announced that this year, for the first time ever, the Muscular Dystrophy Association will be hosting its annual clinical conferences at the same event…

Continue Reading Muscular Dystrophy Association to Host First Annual Combined Conference
AMO Pharma Presents New Rating Scale for Type 1 Myotonic Dystrophy Symptoms
jarmoluk / Pixabay

AMO Pharma Presents New Rating Scale for Type 1 Myotonic Dystrophy Symptoms

A press release from American biopharmaceutical company AMO Pharma, published by PR Newswire, detailed the recent completion of the Company's new congenital myotonic dystrophy type 1 (CDM1) symptom-evaluation scale. The…

Continue Reading AMO Pharma Presents New Rating Scale for Type 1 Myotonic Dystrophy Symptoms
Company Announces Plans for Myotonic Dystrophy and Duchenne Muscular Dystrophy Treatments
rawpixel / Pixabay

Company Announces Plans for Myotonic Dystrophy and Duchenne Muscular Dystrophy Treatments

According to a story from CRWE World, the genetic medicines company Audentes Therapeutics has recently announced its intent to develop new therapies for myotonic dystrophy and Duchenne muscular dystrophy. These…

Continue Reading Company Announces Plans for Myotonic Dystrophy and Duchenne Muscular Dystrophy Treatments

Clinical Trial Initiated for New Technology That Could Allow Amyotrophic Lateral Sclerosis Patients to Communicate

People living with rare diseases such as amyotrophic lateral sclerosis (ALS) or muscular dystrophy as well as those who have suffered from a stroke or spinal cord injury often experience…

Continue Reading Clinical Trial Initiated for New Technology That Could Allow Amyotrophic Lateral Sclerosis Patients to Communicate

Company Announces Plans to File for Conditional Marketing for Duchenne Muscular Dystrophy Drug in the EU

According to a story from Market Screener, the specialty pharmaceutical company Santhera Pharmaceuticals recently released an announcement in which the company revealed its intent to file for Conditional Marketing Authorization…

Continue Reading Company Announces Plans to File for Conditional Marketing for Duchenne Muscular Dystrophy Drug in the EU

The Struggles of being a Rare Disease Patient in China

The State of Rare Diseases in China The Illness Challenge Foundation (ICF) is an organization devoted to easing the burdens that rare disease patients living in China face. They accomplish this…

Continue Reading The Struggles of being a Rare Disease Patient in China

Yet Another Study Shows the Dire Need for More Diversity in Medical Research

A recent study published in Cell has exhibited the scientific community's negligence for conducting research that includes an adequate representation of non-Europeans. Specifically, it showed that 78% of patients in genomic…

Continue Reading Yet Another Study Shows the Dire Need for More Diversity in Medical Research

First Potential Gene Therapy for Tay-Sachs Disease Produces Positive Results at Three Month Mark

Tay-Sachs disease is a rare, genetic and sadly fatal condition. It's a neurodegenerative disorder caused by an impaired production of the β-Hexosaminidase A enzyme (HEXA). Symptoms of this condition include listlessness, diminishing…

Continue Reading First Potential Gene Therapy for Tay-Sachs Disease Produces Positive Results at Three Month Mark
CRISPR Successfully Treats Duchenne Muscular Dystrophy in Mouse Model
Alexas_Fotos / Pixabay

CRISPR Successfully Treats Duchenne Muscular Dystrophy in Mouse Model

According to a story from Fierce Biotech, the results of a year-long study examining the utility of the groundbreaking gene-editing technology CRISPR in treating the rare genetic disorder Duchenne muscular…

Continue Reading CRISPR Successfully Treats Duchenne Muscular Dystrophy in Mouse Model
Passage Bio Receives New Funding to Advance 5 Gene Therapy Projects
Source: Pixabay

Passage Bio Receives New Funding to Advance 5 Gene Therapy Projects

Passsage Bio Passage Bio has just announced that they've received 115.5 million dollars to help advance their development of gene therapies. They will begin by using the funds to further…

Continue Reading Passage Bio Receives New Funding to Advance 5 Gene Therapy Projects
New Funding Program to Support Newborn Screening for Duchenne Muscular Dystrophy
Source: Pixabay

New Funding Program to Support Newborn Screening for Duchenne Muscular Dystrophy

Duchenne Muscular Dystrophy Duchenne muscular dystrophy (DMD) is a rare, progressive, and fatal condition. It primarily affects males (1 out of every 3,600 to 6,000 male births). It's caused by…

Continue Reading New Funding Program to Support Newborn Screening for Duchenne Muscular Dystrophy